GlassScriptPhysician profile
Anne Broad
NPI 1225564248
$2,325.30
in general payments reported to CMS, 2019-2025
28 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $607 · 2023: $849 · 2024: $394 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.55 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $327.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.97 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Dexcom, INC. | $126.66 | 2022-2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $117.76 | 2023-2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $101.48 | 2022-2024 | Rexulti |
| Pfizer INC. | $96.50 | 2022-2025 | |
| Lilly USA, LLC | $95.96 | 2021-2023 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $92.77 | 2022-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $60.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.36 | 2021-2025 | |
| Horizon Therapeutics Plc | $52.67 | 2022-2023 | Tepezza |
| Daiichi Sankyo INC. | $47.06 | 2022-2024 | Injectafer |
| Amgen INC. | $46.65 | 2022-2025 | Otezla, Repatha, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.05 | 2022-2023 | Nucala |
| Nestle Healthcare Nutrition INC. | $44.52 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $42.43 | 2021-2023 | Breztri |
| Teva Pharmaceuticals USA, INC. | $42.19 | 2022 | |
| Sanofi Pasteur INC. | $36.29 | 2023 | |
| Exact Sciences Corporation | $29.59 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $27.96 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $27.07 | 2024 | |
| Hologic Sales and Service, LLC | $25.22 | 2023 | Aptima |
| Indivior INC. | $23.76 | 2024 | Sublocade |
| Eisai INC. | $14.94 | 2021 | |
| Seqirus USA INC | $13.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Broad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.